GRAIL (NASDAQ:GRAL) Insider Sells $91,070.28 in Stock

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares of the company’s stock, valued at $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

GRAIL Price Performance

GRAL stock opened at $59.98 on Monday. The business has a 50 day simple moving average of $57.27 and a 200-day simple moving average of $75.42. The firm has a market capitalization of $2.57 billion, a PE ratio of -5.78 and a beta of 3.15. GRAIL, Inc. has a 1 year low of $29.95 and a 1 year high of $118.84.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. The business had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. On average, equities research analysts expect that GRAIL, Inc. will post -10.99 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Perigon Wealth Management LLC lifted its holdings in GRAIL by 0.7% in the fourth quarter. Perigon Wealth Management LLC now owns 19,450 shares of the company’s stock valued at $1,665,000 after acquiring an additional 133 shares during the last quarter. Parallel Advisors LLC lifted its stake in GRAIL by 5.2% during the fourth quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock worth $228,000 after purchasing an additional 133 shares in the last quarter. Westmount Partners LLC lifted its stake in GRAIL by 1.8% during the fourth quarter. Westmount Partners LLC now owns 8,279 shares of the company’s stock worth $709,000 after purchasing an additional 150 shares in the last quarter. Comerica Bank lifted its stake in GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares in the last quarter. Finally, Whittier Trust Co. lifted its stake in GRAIL by 19.3% during the fourth quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock worth $95,000 after purchasing an additional 180 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Morgan Stanley decreased their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Robert W. Baird set a $70.00 price objective on GRAIL in a report on Wednesday, May 6th. Piper Sandler upped their price objective on GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Mizuho assumed coverage on GRAIL in a report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price objective on the stock. Finally, Canaccord Genuity Group decreased their price objective on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GRAIL has an average rating of “Hold” and an average price target of $67.00.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.